logo
logo
COR stock ticker logo

Cencora, Inc.

NYSE•COR
CEO: Mr. Steven H. Collis
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 1995-04-04
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Contact Information
1 West First Avenue, Conshohocken, PA, 19428-1800, United States
610-727-7000
www.cencora.com
Market Cap
$68.08B
P/E (TTM)
41.8
32.9
Dividend Yield
0.7%
52W High
$377.54
52W Low
$252.49
52W Range
78%
Rank13Top 2.2%
6.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$85.93B+0.00%
4-Quarter Trend

EPS

$2.88+0.00%
4-Quarter Trend

FCF

-$2.42B+0.00%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Revenue Growth Strong Revenue reached $85.93 B USD for the quarter, marking a solid 5.5% increase over the prior year period.
Gross Profit Surges Gross profit surged to $3.07 B USD, showing a strong 20.1% increase driven by recent acquisitions.
Net Income Improvement Net income attributable to Cencora grew to $559.65 M USD, improving significantly from $488.60 M USD last year.
Operating Cash Usage Down Cash used in operating activities decreased by $0.4 B USD, totaling $2.31 B USD utilized this quarter.

Risk Factors

Opioid Litigation Liability Accrued litigation liability for opioid settlements stands at $4.3 B USD, payable across the next thirteen years.
Asset Impairment Recorded Management recorded a $165.7 M USD goodwill impairment charge related to the U.S. Consulting Services business sale.
Interest Expense Spikes Net interest expense increased substantially by 159.2% due to significant new debt issuance for acquisitions.
Geopolitical Uncertainties Remain Exposure remains high regarding geopolitical uncertainties, macroeconomic shifts, and potential supply chain disruptions globally.

Outlook

OneOncology Acquisition Closed The company finalized the majority acquisition of OneOncology for approximately $4.6 B USD cash in February 2026.
New Segment Reporting A new business reporting structure aligning with growth priorities was implemented starting in the first quarter of fiscal 2026.
Credit Facility Expanded The Multi-Currency Revolving Credit Facility was amended, increasing total commitments available up to $5.5 B USD.
Quarterly Dividend Raised Anticipating continued capital needs, the Board increased the quarterly common stock dividend by 9% to $0.60 USD.

Peer Comparison

Revenue (TTM)

MCK stock ticker logoMCK
$397.96B
+15.5%
COR stock ticker logoCOR
$325.78B
+7.4%
CAH stock ticker logoCAH
$244.49B
+10.1%

Gross Margin (Latest Quarter)

ARGX stock ticker logoARGX
89.3%
-53.8pp
REGN stock ticker logoREGN
85.0%
+3.3pp
EW stock ticker logoEW
78.3%
-2.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MCK$116.13B26.7-245.3%10.2%
REGN$77.49B17.014.8%6.7%
COR$68.08B41.8101.4%10.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.4%
Moderate Growth
4Q Net Income CAGR
-8.0%
Declining Profitability
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:May 5, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data